Indaptus Therapeutics, Inc.
INDPHealthcare|Biotechnology|US
$3.32
+0.16 (+5.06%)
DCF Value
$8.29
Tangible Book / Share
$0.10
Cash / Share
$0.10
Analyst Consensus
Buy2 analysts
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
Rating Trend
Mar 25
2 buy · 0 hold · 0 sell
Apr 25
2 buy · 0 hold · 0 sell
May 25
1 buy · 0 hold · 0 sell
Jun 25
1 buy · 0 hold · 0 sell
Jul 25
1 buy · 0 hold · 0 sell
Aug 25
1 buy · 0 hold · 0 sell
Sep 25
1 buy · 0 hold · 0 sell
Oct 25
1 buy · 0 hold · 0 sell
Nov 25
1 buy · 0 hold · 0 sell
Dec 25
1 buy · 0 hold · 0 sell
Jan 26
1 buy · 0 hold · 0 sell
Feb 26
1 buy · 0 hold · 0 sell
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | Nov 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2023 |
| HC Wainwright & Co. | maintain | Overweight | Mar 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 8, 2023 |
| Maxim Group | upgrade | Hold →Buy | Oct 19, 2021 |
Earnings History
Next report: Nov 17, 2026 · EPS est. $-1.46| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.02 | $-0.02 | — | — |
| May 15, 2026 | $-0.23 | $-1.87 | — | — |
| Mar 17, 2026 | $-3.10 | $-4.36 | — | — |
| Nov 12, 2025 | $-2.98 | $-4.17 | — | — |
| Aug 11, 2025 | $-9.09 | $-10.08 | — | — |
| May 14, 2025 | $-8.96 | $-11.48 | — | — |
| Mar 13, 2025 | $-10.64 | $-0.44 | — | — |
| Nov 12, 2024 | $-8.96 | $-0.47 | — | — |
News
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update.
Aug 13, 2026globenewswire.com